AstraZeneca's Latest Data on Rare-Disease Drug Supports Sales Potential
Dow Jones
Oct 12
0559 GMT - AstraZeneca's latest data on experimental rare-disease drug efzimfotase alfa supports the medicine's potential for use beyond children and its sales prospects, analysts at Citi say in a research note. The U.K. drugmaker has already filed for U.S. approval for the drug to treat rare condition hypophosphatasia in children aged 2 and older, and detailed results of a study in adolescents and adults reported over the weekend could pave the way for a broader approval, according to Citi. "We see the data as supportive of approval and use in the adult/adolescent setting," the analysts say. This, in turn, could bring the medicine's peak-sales potential closer to Citi's estimate of $4.4 billion than the current consensus of $2.4 billion, they add.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.